ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B

2008 ◽  
Vol 42 (2) ◽  
pp. 160-164 ◽  
Author(s):  
M.J. ter Borg ◽  
B.E. Hansen ◽  
G. Bigot ◽  
B.L. Haagmans ◽  
H.L.A. Janssen
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Ifn Alpha ◽  
Positive Chronic Hepatitis

STUDYING THE EFFICACY OF TENOFOVIR IN THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B

2014 ◽  
pp. 55-59
Author(s):  
Xuan Chuong Tran ◽  
Van Huy Tran
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
High Viral Load ◽  
Hbv Dna ◽  
University Hospital ◽  
Baseline Viral Load ◽  
Biochemical Response ◽  
Positive Chronic Hepatitis

Background: The HBeAg-positive chronic hepatitis B is the type of chronic hepatitis with active virus replication, has high viral load and difficult to treat. We evaluate the effects of treatment with tenofovir in HBeAg-positive chronic hepatitis B patients. Aims: Evaluate the treatment results in patients with HBeAg-positive chronic hepatitis B. Patients and methodes: HBeAg-positive chronic hepatitis B patients over 15 yrs treated at Hue University Hospital from Jan. 2012 to Dec. 2013. Results: Most of symptoms disappeared after 12 months. More than 85% patients have biochemical response. 81.8% patients have undetectable HBV DNA. Rate of HBV DNA decrease according to the baseline viral load. After 12 months 27.3% patients loss HBeAg and 20.5% have anti-HBe. Conclusions: Clinical and biochemical response were relatively high. 81.8% patients have undetectable HBV DNA. After 12 months 27.3% patients loss HBeAg and 20.5% have anti-HBe. Key words: HBeAg-positive chronic hepatitis B, HBV DNA

Sign in / Sign up

Export Citation Format

Share Document